Saturday 17 October 2026 Export STIM’s income statement to Excel — free account

Neuronetics, Inc.

Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.08%, EPS grew 66.7%, free cash flow grew 62.1% and total debt rose 10.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

1.89 0.06 −3.08%

Follow STIM

Alert me

Market cap: $148.6M
P/E: 0.0×
Fwd P/E: −2.8×
Dividend yield: —
F-score: 4/9
Altman Z: −3.48
Beneish M: −2.59
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 4.81

Total sells 0.28

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	6	1	2	—	1	1	—	—
Sell	—	—	—	6	5	—	—	—	—	—	—	—

Insider Ownership 60.51%

Capital & Financial Ratios $m

Market Cap 148.58

Revenue 155.10

Net Income (30.85)

Free Cash Flow (11.22)

Net Debt 36.34

Current Ratio 1.88

Debt/Equity 2.84

P/E ratio 0.00

Fwd P/E (2.78)

P/S ratio 0.89

P/B ratio 6.39

Past 5Y EPS Growth —

This Y EPS Growth 40.95%

Next Y EPS Growth 19.82%

Next Y revenue growth 8.61%

Next 5Y EPS Growth 26.75%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 28.35%

10-year low 10-year high

P/B against its own 10 years 88.82%

10-year low 10-year high

EV/Sales against its own 10 years 50.17%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	61	20	34	25
Receivables	18	24	17	16
Inventory	8	4	4	6
Other	—	—	—	—
	94	58	62	53

	2023	2024	2025	Q'26
Payables	5	11	11	12
ST’ Debt	—	—	—	—
Other	—	1	1	0
	20	31	31	28

Compound Annual Growth %

	10y	5y	3y
Sales	—	24.81%	31.76%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.58%	(22.81%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	34	42	—	—	—
’25	32	38	37	42	149
’24	17	16	19	22	75
’23	16	18	18	20	71
’22	14	16	16	18	65
’21	12	14	14	15	55
’20	11	10	12	16	49

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(1)	—	—	—
’25	(17)	(4)	(1)	1	(20)
’24	(12)	(5)	(5)	(9)	(31)
’23	(15)	(9)	(10)	2	(32)
’22	(12)	(9)	(7)	(3)	(31)
’21	(9)	(6)	(9)	(5)	(28)
’20	(14)	(9)	(4)	(2)	(28)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(1)	—	—	—
’25	(17)	(4)	(1)	1	(21)
’24	(12)	(6)	(6)	(9)	(32)
’23	(15)	(10)	(11)	1	(34)
’22	(13)	(10)	(7)	(4)	(34)
’21	(10)	(6)	(9)	(5)	(30)
’20	(14)	(10)	(4)	(2)	(29)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.16)	(0.05)	—	—	—
’25	(0.21)	(0.15)	(0.13)	(0.10)	(0.59)
’24	(0.27)	(0.33)	(0.44)	(0.33)	(1.37)
’23	(0.38)	(0.17)	(0.33)	(0.19)	(1.05)
’22	(0.41)	(0.39)	(0.28)	(0.30)	(1.38)
’21	(0.31)	(0.29)	(0.31)	(0.29)	(1.22)
’20	(0.68)	(0.41)	(0.18)	(0.19)	(1.46)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	15.40	3.96	1.25	3.75	1.98	1.03	0.52	1.25	Analyst estimates 2026–2028 Powerpack
	High	—	—	39.39	19.85	11.71	22.43	6.92	6.95	5.07	5.92
People
People	Employees	—	167	133	235	126	175	194	203	716	658
	Revenue/emp, $m	0.00	0.24	0.40	0.27	0.39	0.32	0.34	0.35	0.10	0.23
Income, $m
Income, $m	Revenue	34	40	53	63	49	55	65	71	75	149
	Gross margin, %	80.65	76.18	76.42	75.44	76.54	78.93	76.26	72.47	72.32	48.48
	EBT	(11)	(16)	(24)	(29)	(27)	(31)	(37)	(30)	(44)	(39)
	EBT margin, %	(32.82)	(39.72)	(45.66)	(46.35)	(55.75)	(56.39)	(56.99)	(42.31)	(58.39)	(26.24)
	Net income	(11)	(16)	(24)	(29)	(27)	(31)	(37)	(30)	(44)	(39)
	Depreciation	1	1	1	1	1	1	2	2	2	3
Per share, $
Per share, $	Revenue	234.44	217.38	5.90	3.41	2.61	2.17	2.42	2.49	2.36	2.26
	Earnings	(76.95)	(86.34)	(2.69)	(1.58)	(1.46)	(1.22)	(1.38)	(1.05)	(1.37)	(0.59)
	Cash flow	(58.50)	(59.91)	(2.30)	(1.66)	(1.51)	(1.10)	(1.14)	(1.12)	(0.98)	(0.31)
	Capex	(2.22)	(3.19)	(0.11)	(0.04)	(0.04)	(0.09)	(0.12)	(0.08)	(0.05)	(0.01)
	Free cash flow	(60.72)	(63.11)	(2.41)	(1.70)	(1.55)	(1.19)	(1.26)	(1.20)	(1.02)	(0.32)
	Book value	(32.97)	(29.66)	7.94	2.60	1.35	3.34	2.12	1.19	1.00	0.40
	Shares, m	0	0	9	18	19	25	27	29	32	66
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	3.28	1.32	4.25	2.05	2.72	1.10	0.68	0.61
	P/B	0.00	0.00	2.44	1.72	8.21	1.33	3.11	2.31	1.61	3.47
	EV/Sales	0.00	0.00	1.97	0.59	3.93	0.96	2.17	1.10	1.34	0.91
	EV/FCF	(0.19)	(0.19)	(4.81)	(1.19)	(6.65)	(1.76)	(4.16)	(2.28)	(3.09)	(6.43)
Cash, $m
Cash, $m	Operating cash flow	(9)	(11)	(21)	(30)	(28)	(28)	(31)	(32)	(31)	(20)
	Capex	0	(1)	(1)	(1)	(1)	(2)	(3)	(2)	(1)	(1)
	Free cash flow	(9)	(12)	(22)	(31)	(29)	(30)	(34)	(34)	(32)	(21)
Balance, $m
Balance, $m	Working capital	10	25	101	61	51	100	66	74	27	31
	Total debt	20	30	30	31	35	36	36	59	55	66
	Net debt	3	0	(74)	(45)	(16)	(60)	(36)	(1)	35	31
	Shareholders’ equity	(5)	(6)	71	48	25	85	57	34	32	26
Returns, %
Returns, %	ROA	(35.25)	(50.39)	(30.90)	(26.75)	(30.70)	(28.37)	(28.79)	(25.95)	(34.05)	(27.61)
	ROIC	0.00	0.00	0.00	(697.81)	(141.37)	(69.35)	(103.82)	(58.06)	(32.11)	(34.06)
	ROE	6.08	8.69	39.63	(48.86)	(74.86)	(56.37)	(52.25)	(66.17)	(132.47)	(134.39)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PROF Profound Medical	$230.5M	— (loss-making)	— (loss-making)	+12.30% (above 0%: growing)	n/m	+17.51% (above 0%: growing)	78.41%	(445.67%)	Compare
RXST RxSight, Inc.	$194.2M	— (loss-making)	— (loss-making)	+0.31% (above 0%: growing)	n/m	−94.39% (below 0%: shrinking)	76.72%	(40.81%)	Compare
INGN Inogen, Inc	$167.1M	— (loss-making)	— (loss-making)	+3.04% (above 0%: growing)	n/m	−51.15% (below 0%: shrinking)	45.51%	(5.36%)	Compare
STIM Neuronetics, Inc.	$148.6M	— (loss-making)	— (loss-making)	+9.08% (above 0%: growing)	n/m	+62.06% (above 0%: growing)	51.06%	(3.61%)
QTRX Quanterix Corporation	$145.2M	— (loss-making)	— (loss-making)	+34.44% (above 0%: growing)	n/m	+18.92% (above 0%: growing)	38.52%	(150.22%)	Compare
MXCT MaxCyte, Inc.	$134.2M	— (loss-making)	— (loss-making)	−14.53% (below 0%: shrinking)	n/m	+54.74% (above 0%: growing)	76.96%	(140.72%)	Compare
OWLT Owlet, Inc.	$129.8M	— (loss-making)	— (loss-making)	+29.94% (above 0%: growing)	n/m	+55.74% (above 0%: growing)	64.44%	5.14%	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
Median of peers	$139.7M	—	—	+17.19%	—	+5.24%	64.17%	(90.77%)

All 149 Medical Devices stocks →

Neuronetics, Inc. (STIM) key facts

Strength: Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024.
Neuronetics, Inc. (STIM) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, STIM traded at $1.89, a market capitalization of $148.6 million.
Return on equity was −134.4% and debt-to-equity 2.84.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −3.48 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.